Molecular biomarkers in endometrial hyperplasias predict cancer progression

Citations of this article
Mendeley users who have this article in their library.


Objective: The purpose of this study was to assess the value of the 2003 World Health Organization (WHO) and endometrial intraepithelial neoplasia (EIN) classifications, D-score, and molecular biomarkers in endometrial hyperplasia (EH) for cancer progression. Study Design: We conducted a review of 307 endometrial hyperplasias for WHO and EIN classifications and an analysis of biomarkers, D-score, and cancer progression-free survival. Results: The WHO, EIN, D-score, and many biomarkers were prognostic; 7.2% of the samples progressed to cancer. The WHO and EIN classifications correlated weakly with CK5/6 and p16. The D-score was strongest prognostically. When >1, it had the lowest false-negative progression rate of all features analyzed. COX2 negativity was the only other independent multivariate cancer progression predictor in endometrial hyperplasia, but only in cases with D-score <1. Eight of 13 cases (61%), with a combined D-score of <1 and negative COX2 progressed, which contrasted with 3 of 139 of all other cases (2.8%) (P < .0001; hazard ratio, 53.0). The biomarkers did not strengthen the prognostic value of the WHO or EIN classification. Conclusion: Combined D-score <1 and COX2 negativity strongly predict cancer progression in endometrial hyperplasias. © 2011 Mosby, Inc. All rights reserved.




Steinbakk, A., Gudlaugsson, E., Aasprong, O. G., Skaland, I., Malpica, A., Feng, W., … Baak, J. P. (2011). Molecular biomarkers in endometrial hyperplasias predict cancer progression. American Journal of Obstetrics and Gynecology, 204(4), 357.e1-357.e12.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free